Loading...
•
Jun 30, 2023
Aytu BioScience Q4 2023 Earnings Report
Aytu BioPharma reported record revenues, prescriptions, and adjusted EBITDA for Q4 2023.
Key Takeaways
Aytu BioPharma reported a strong Q4 2023 with record revenues of $30.7 million, a 12% increase year-over-year, and a positive Adjusted EBITDA of $7.7 million. The company's Rx segment drove growth with record prescriptions and revenues, while the Consumer Health segment is being de-emphasized to improve profitability. Aytu is focusing on its core Rx segment and expects to achieve net income going forward.
Total net revenue reached $30.7 million, a 12% increase year-over-year.
Rx segment net revenue was $23.3 million, a 24% increase year-over-year.
Total quarterly promoted Rx product prescriptions increased 32% year-over-year to 155,562.
Adjusted EBITDA was a positive $7.7 million, compared to a negative $3.9 million in the year-ago quarter.
Revenue by Segment
Forward Guidance
Aytu BioPharma expects continued growth of the Rx Segment in fiscal 2024 and believes it is well-positioned to cover operational expenses and drive shareholder value.
Positive Outlook
- Continued growth of the Rx Segment in fiscal 2024
- Well-positioned to cover operational expenses
- Drive shareholder value
- Manufacturing transfer of Adzenys XR-ODT and Cotempla XR-ODT can materially add to ADHD gross profit margins.
- Company expects a six-month review of the PAS submission, which would enable FDA approval by late calendar 2023 or early calendar 2024
Challenges Ahead
- Winding down the Consumer Health segment
- Suspension of all pipeline development programs
- Dependence on Rx Segment growth
- Reliance on third-party manufacturers
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...